Von Potter

Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial

Antonio Omuro, Alba A. Brandes, Ahmed Idbaïh et al. · Neuro-Oncology · 2022 · 485 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Marwan Fakih, Kanwal Raghav, David Chang et al. · Journal of Clinical Oncology · 2021 · 74 citations

Pharmacy, Oncology, Pharmacotherapy +12

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143

Antonio Omuro, David A. Reardon, John H. Sampson et al. · Neuro-Oncology Advances · 2022 · 69 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature

Muhammad Wasif Saif, Jennifer Peccerillo, Von Potter · Cancer Chemotherapy and Pharmacology · 2008 · 45 citations

Medicine, Immunology, Oncology +12

Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

Michael Lim, Antonio Omuro, Gordana Vlahovic et al. · Annals of Oncology · 2017 · 20 citations · Full text

Medicine, Oncology, Pharmacotherapy +14